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Abstract  
Metal-based drugs have drawn significant attention over the past few decades due to their 
advanced properties and benefits in biomedical therapeutic and diagnostic systems. In the 
current work two Schiff bases, 4-methyl-2,6-bis-(pyridin-2-yl-hydrazonomethyl)-phenol  (L1), 
and methyl-phenol-di-S-methyl dithiocarbazate (L2), and their corresponding zinc complexes, 
[Zn2(L1)(OAc)3] (C1) and [Zn2(L2)(OAc)] (C2) (OAc: CH3COO
−) were synthesized. All 
compounds were characterized by elemental analyses, FTIR, UV–Vis and NMR spectroscopies 
and ESI-MS spectrometry. The stability of the compounds was evaluated under physiological 
conditions (5 % DMSO and 95 % PBS, pH 7.4). The interaction of Schiff bases and their 
corresponding Zn(II) complexes with biomolecules namely, bovine serum albumin (BSA) and 
calf thymus DNA (ctDNA) was investigated using UV-Vis, circular dichroism (CD) and 
fluorescence spectroscopies under physiological pH and 298 K. Fluorescence quenching of 
BSA upon interaction with the compounds was analysed using the Stern-Volmer formalism 
which revealed moderate to strong binding to serum albumin with binding constant values of  
KB=2.36x10
3 and 2.38x105M−1, for C1 and C2 respectively. These results reveal good binding 
propensity in comparison with the ligands. Changes in the secondary structure of BSA are 
imposed by the Schiff base ligands and Zn(II) complexes as revealed by CD spectroscopy. 
Additionally, hypochromicity in the UV-Vis absorption spectra of the complexes upon addition 
of BSA further corroborates interaction between the protein and the complex. The complexes 
were tested for their DNA binding ability by UV-Vis and CD spectroscopy and the results 
indicate that there is interaction between the complexes and DNA where C1 has better binding 
tendency toward DNA than C2. Cytotoxic activity of L1 and L2 studied with several tumour 
cell lines (Caco-2, MCF-7 and PC-3) and normal cell, NHDF, showed that the compounds are 
cytotoxic to all cell lines tested, without selectivity towards cancer cells.  Overall, the IC50 
values are comparable with the ones obtained for the positive control, fluorouracil. The two 
ligands and one complex were tested against several strains of bacteria and fungi and promising 
results were obtained, where L1 is active against L. monocytogenes, L2 is active against K. 
pneumoniae, A. baumannii and S. aureus and C1 against L. monocytogenes and S. aureus. L2 
showed better activity against the tested microorganisms compared to L1 and the metal 
complex. 
 
Keywords: Schiff bases, Zn(II) complexes, cytotoxicity, albumin, DNA. 
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Resumo 
Nas últimas décadas os fármacos à base de metais de transição têm sido alvo de grande atenção 
devido às suas propriedades e benefícios em sistemas terapêuticos e de diagnóstico. Neste 
trabalho, sintetizaram-se duas bases Schiff, 4-metil-2,6-bis-(piridina-2-il-hidrazonometil)-
fenol (L1), e ditiocarbazato de metil-fenol-di-S-metilo (L2), e dois complexos, 
[Zn2(L1)(OAc)3] (C1), e [Zn2(L2)(OAc)] (C2). Os compostos foram caracterizados por análise 
elementar, espectroscopias de FTIR, UV-Vis, RMN e por espectrometria de massa. A 
estabilidade dos compostos foi avaliada em condições fisiológicas (5% de DMSO e 95% de 
PBS, pH 7.4). A interação das bases Schiff e seus complexos de Zn(II) com biomoléculas, 
nomeadamente albumina sérica bovina (BSA) e DNA do timo de bezerro (ctDNA), foi 
investigada usando espectroscopia de UV-Vis, dicroísmo circular (DC) e fluorescência, a pH 
fisiológico e 298 K. Analisou-se a extinção da fluorescência da BSA após interação com os 
compostos usando o formalismo de Stern-Volmer, que revelou ligação moderada a forte à 
albumina sérica, tendo sido obtidos valores de constantes de ligação de 2.36x103 e 2.38x105 M-
1, para C1 e C2, respectivamente. Estes resultados revelam maior afinidade dos complexos pela 
BSA, quando comparados com os ligandos. Alterações na estrutura secundária da BSA são 
impostas pelos complexos de Zn(II), conforme revelado por espectroscopia de DC. 
Adicionalmente, a hipocromicidade observada nos espectros de absorção no UV-Vis, após a 
adição de BSA, corrobora a interação entre a proteína e os complexos. Os complexos foram 
testados quanto à sua capacidade de ligação ao DNA recorrendo à espectroscopia UV-Vis e 
DC, e os resultados indicam que há interação entre os complexos e o DNA, e que C1 tem mais 
afinidade pelo DNA do que C2. A atividade citotóxica de L1 e L2, estudada em várias linhas 
tumorais (Caco-2, MCF-7 e PC-3) e numa linha normal (NHDF), mostraram que os compostos 
são citotóxicos para todas as linhas celulares testadas, sem seletividade para as células 
cancerígenas. No geral, os valores de IC50 são comparáveis aos obtidos para o controlo positivo, 
fluorouracil. Os ligandos e C1 foram testados contra várias estirpes de bactérias e fungos e 
foram obtidos resultados promissores.  L1 é ativo contra L. Monocytogenes, L2 é ativo contra 
K. pneumoniae, A. baumannii e S. aureus e C1 contra L. monocytogenes e S. aureus. L2 foi o 
que apresentou maior atividade contra os microorganismos testados, quando comparado com 
L1 e C1. 
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1. Introduction 
The discovery of novel active compounds with new mechanisms of action, higher efficacy and 
improved selectivity is a matter of urgency to multi drug resistance and toxicity problems 
associated with many therapeutic drugs [1]. Great attention has been given to transition metal 
complexes and extensive biological effects have been found for many of them [2]. One of the 
first therapeutic metallodrugs was salvarsan (Fig. 1a), an arsenic-based antimicrobial agent 
developed by Paul Ehrlich for the treatment of syphilis. With the addition of mercury and 
bismuth, salvarsan remained the standard remedy for syphilis until it was replaced by penicillin 
after World War II. Salvarsan is regarded as the birth of modern chemotherapy and often cited 
as the beginning of modern research and development of metallodrugs. In 1965, the star of the 
field, the anticancer agent cisplatin, was discovered by Barnett Rosenberg and Loretta Van 
Camp at Michigan State University [3]. This platinum-based anticancer drug (Fig. 1b) has 
played a crucial role in Medicinal Chemistry. Complexes with other metal ions like titanium 
and ruthenium are also being explored with some success but none of them have been used in 
the clinic yet [2,4]. 
Despite the achievements in the metal-based drugs, especially those of platinum, they are still 
associated with many drawbacks such as general toxicity, nonspecific targeting and acquired 
drug resistance, which has stimulated researchers to seek and develop more effective, less 
toxic, and target-specific metal-based drugs [5]. Complexes based on essential transition 
metals, such as Co(II), Ni(II), Cu(II) and Zn(II) have been found interesting in this respect. 
These metal ions are biocompatible, endogenous and they are present in biological systems 
[4,5]. They are nowadays present in several inorganic drugs used against a variety of diseases 
[4].  
 
Figure 1 Salvarsan (a) and cisplatin (b) metallodrugs [3]. 
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Transition metal complexes possess several advantages that make them attractive alternatives 
to small organic molecules for the development of therapeutic agents. They can adopt 
numerous geometries, including square-planar, square-pyramidal, trigonal-bipyramidal and 
octahedral, depending on the coordination number of the metal ion. Many of these geometries 
are unavailable to purely organic molecules, which are limited to linear, trigonal planar or 
tetrahedral shapes because carbon cannot exceed a coordination number of four. The diversity 
of molecular structures afforded by transition metal complexes may therefore allow them to 
sample regions of the chemical space that are inaccessible to organic molecules. Moreover, 
metal complexes can undergo redox reactions and ligand-exchange reactions inside the body, 
allowing for unique mechanisms of action to take place [6]. In general, because of the intrinsic 
nature of their centres, characteristic coordination modes, accessible redox states and kinetic 
properties allow metal complexes to offer potential advantages over organic agents alone [2]. 
However, the role of the ligands in the metal complex is also very important. For example, they 
control the reactivity of the metal and determine the nature of interactions involved in the 
recognition of biological target sites such as deoxyribonucleic acid (DNA), enzymes and 
protein receptors. Therefore, the choice of ligands for the formation of metal-based drugs is 
crucial. As a result, a great expansion of research in the coordination chemistry of sulphur and 
nitrogen containing ligands such as Schiff bases and phenanthroline derivatives has taken place 
during recent years [7,8]. 
1.1 Schiff-base ligands 
Schiff-base ligands and corresponding metal complexes have received much attention in recent 
years due to their wide use as dyes and pigments, catalysts, intermediates in organic synthesis, 
polymer stabilizers and due to their broad range of biological activities, including anti-fungal, 
anti-bacterial, anti-malarial, anti-proliferative, anti-inflammatory, anti-viral, and anti-pyretic 
properties [9-12]. Schiff bases are aldehyde or ketone like compounds in which the carbonyl 
group is replaced by an imine or azomethine group. It contains a carbon-nitrogen double bond 
with the nitrogen atom connected to an aryl or alkyl group but not hydrogen. 
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Figure 2 The structure of a Schiff base. 
Schiff bases are of general formula R1N=CR2R3, where R1 is a phenyl or alkyl group which 
gives the Schiff base its stability [13]. Although the formation of Schiff bases is reversible, due 
to the hydrolysis of the imine under certain conditions, it is still straight-forward for the reaction 
to succeed. It is still unknown why some types of Schiff bases are stable in the presence of 
water even in acidic solution, while others are very sensitive to water and easily hydrolyse back 
to aldehyde (or ketone) and amine.  
To overcome this potential hydrolysis, the reaction of Schiff bases should be undertaken under 
dry solvent conditions or using some additional procedure to remove the side product, water. 
The lone pair on the nitrogen atom of the imine can supply electrons, which enable the 
formation of a proper donor bond to a metal ion for complexation to occur. Many Schiff bases 
have a second functional group, normally OH and SH groups or another N atom, which are 
near the imine group. These functional groups can allow the formation of five or six membered 
chelate rings when coordinated with different metal ions. 
1.2 History of Schiff-bases  
Schiff bases are named after Hugo (Ugo) Schiff (1834-1915), a German chemist. He discovered 
Schiff bases in 1864 and other imines and was responsible for research into aldehydes and had 
the Schiff test named after him. Fuchsine (shown in Figure 3) was studied by Schiff as a Schiff 
reagent in 1866, which was apparently widely used during the last decades of the 19th century 
for industrial dyes. 
 
Figure 3 Structure of fuchsine. 
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A well-known Schiff base is salen [14], which stands for N,N′-ethylenebis(salicylaldimine) 
(Figure 4), a bi-functional and tetradentate (ONNO) ligand. Several asymmetric salen type 
Schiff bases were reported by R. Atkins [15] in 1985, who suggested a more general term for 
these tetradentate (ONNO) ligands: salen-type. The 2-hydroxybenzaldehyde is a suitable 
building block due to the possible substitution patterns of the aromatic ring. Once the imine 
bond is formed from primary amine and aldehyde, this orientation of salen-type Schiff bases 
will form a more stable six-member ring when binding to metal ions. 
 
Figure 4 Typical structure of salen-type ligands. 
1.3 Synthesis of Schiff-base ligands  
The Schiff base reaction is a reversible, usually acid-catalysed condensation between a primary 
amine (not ammonia) and either an aldehyde or a ketone. The Schiff base is the nitrogen 
analogue of an aldehyde or ketone, in which the carbonyl group is replaced by an imine group 
(C=N-R), which is shown in Scheme 1 where R may be an alkyl or an aryl group. 
 
Scheme 1 The synthesis of Schiff Bases. 
Schiff bases, which contain aryl substituents, are more stable and more easily synthesized than 
those containing alkyl substituents. This means that Schiff bases of aliphatic aldehydes are 
relatively unstable, and they readily undergo polymerisation in comparison to products from 
conjugation of aromatic aldehydes [16-20]. Typically, the formation of Schiff bases from 
aldehydes or ketones requires a protic solvent sufficiently dry to prevent potential hydrolysis 
of the newly formed imine bond. The formation is generally undertaken under acid or base 
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catalysis, or upon heating. The completion of imine formation is controlled by the separation 
of the product or removal of water, or both. 
1.4 Mechanism of Schiff bases formation  
The mechanism of Schiff base formation, as shown in Scheme 2, involves a nucleophilic 
addition to the carbonyl group. In the Schiff base formation, the nucleophile is the primary 
amine. In the first part of the mechanism, the lone pair of electrons in the amine nitrogen attacks 
the aldehyde or ketone to give an unstable addition compound called a carbinolamine [21]. A 
1,3-hydrogen shift follows, which facilitates the loss of water by either acid or base catalysis. 
Since the carbinolamine is an alcohol, it undergoes acid catalysed dehydration. 
 
Scheme 2  Mechanism of acid catalysed Schiff base formation. 
The rate-determining step of Schiff base formation is the dehydration of carbinolamine, and 
that is the reason why the reaction is catalyzed by acids or Lewis acids. But the concentration 
of acid present for the catalysis cannot be too high as amines are basic compounds. If the amine 
is deprotonated and becomes non-nucleophilic, equilibrium is pulled to the left and the 
carbinolamine will go back to aldehyde or ketone and primary amine.  
Base catalysis is also used for the dehydration of carbinolamines. The reaction of elimination 
is analogous to the E2 elimination of alkyl halides. Schiff base formation can be divided into 
two steps through an anionic intermediate, i.e. addition followed by elimination. Generally, the 
geometry of the imine double bond adopts a trans orientation, which limits steric interactions 
of the bulkier R and R’ groups, [22].  
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1.5 Compartmental Schiff base ligands  
The chemistry of phenoxo compounds has a great interest in the design of compartmental 
ligands to study the interaction in polynuclear metal complexes. Compartmental ligands 
contain two adjacent, similar to dissimilar compartments, which can coordinate two identical 
or different metal ions in proximity as shown in Figure 5. The donor groups of these ligands 
provide a significant diversification of the coordination sites making them good candidates for 
metal ion complexation and for mimicking biological systems.  
The synthesis of metal complexes using such dinucleating ligands has spurred interest due to 
their potential applications found in various modern research fields including bioinorganic 
chemistry, among others [23]. Among various kinds of dinucleating ligands, the phenol-based 
compartmental ligands of the “end-off” type, possessing two chelating arms attached to the 2- 
and 6-positions of the phenol ring have attracted a great number of researchers [24]. This is 
due to the key role played by the phenolic group which has many useful electronic and 
structural characteristics such as: (i) charge as function of pH values; (ii) bridging capability, 
often the phenolic donor atom binds two metal centres in proximity; (iii) the benzene ring 
allows a great synthetic flexibility. 
 
Figure 5 Compartmental symmetrical ligand. 
1.6 Schiff-base metal complexation  
1.6.1 Overview  
Schiff bases are very efficient ligands. The presence of the lone pair of electrons on the nitrogen 
atom of the imine bond means that they can be donated to the appropriated metal ion. Many 
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Schiff bases have a second or even third functional group, such as an OH, SH and nitrogen 
atoms from heterocyclic rings, e.g. pyridine or imidazole rings. This electron donation, in 
conjunction with a functional group, implies that a vast number of transition metal complexes 
could be prepared. From recent reviews, large numbers of Schiff base complexes have been 
used in catalysis [12], polymer supported in oxidations [11], biological applications [10], and 
so on. 
1.6.2 Zn(II) Schiff-base complexes  
Zinc occurs in low amounts in nature, but, large amounts of zinc ores have been found in the 
Earth’s crust [25]. Zinc is a late first row transition metal which has an electronic configuration 
of [Ar]3d104s2 and is a member of group 12 of the periodic table. The chemistry of zinc is 
controlled by the +2 oxidation state. When Zn is formed in this state, the outer shell s-electrons 
are lost, which yields a bare zinc ion with electronic configuration [Ar]3d10. The full d-orbitals 
imply that Zn(II) complexes are diamagnetic and usually colourless. It also means that the 
coordination complexes of Zn(II) ions do not have a ligand field stabilisation effect. The stereo-
chemistries of these species are determined by considerations of electrostatic forces, covalent 
bonding forces and the size of the metal ion [26].  
Zinc Schiff base complexes are well known in coordination chemistry, although not in such 
large numbers as reported for copper and nickel derivatives. The Zn(II) ion is dominated by 
either four-, five- or six-coordinate geometry with the four- and five-coordinate geometries 
being the most common [26]. Examples of high/low coordination numbers for Zn2+ ions are 
rare, but still can be found. Sun and co-workers [27] reported a pentadentate Schiff base ligand 
in 2006 and established the Zn(II) complex was seven-coordinate with a pentadentate N3O2 
Schiff base ligand and two remaining coordination sites occupied by donor solvent molecules. 
Chisholm and co-workers synthesized a three-coordinate monomeric Zn(II) Schiff base 
complex in 2001 [28]. Six-coordinated Zn(II) Schiff bases complexes are much more common 
than either the seven- or three-coordinate, Yang and co-workers reported a six-coordinated 
Zn(II) complex by two N,N’O-tridentate Schiff base ligands, resulting in a slight distorted 
trans-ZnO2N4 octahedral coordination for the metal ion [29].  
Although Zn(II) Schiff bases complexes showed lower catalytic activity (e.g. Zn(II) Schiff base 
complexes achieved low activity for the decomposition of hydrogen peroxide (H2O2)
 [30] than 
complexes of other metal ions (Ni, Co, Mn or Cu), it showed a wide range of  bio-applications 
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as reviewed by Anand [10]. The interaction of a Zn(II) Schiff base complex with DNA was 
reported by Kumaran and co-workers [31]. It was investigated with in silico methods and 
suggested that it could bind DNA though the minor groove and have high activity on anti-
bacterial and antifungal testing. 
1.7 Biological screening 
The physical and chemical properties of compounds determine their biological activities. For 
example, the rate of absorption, distribution, metabolism and excretion (ADME) of drugs are 
critical parameters in determining their pharmacokinetics properties. This means that the level 
of efficacy and toxicity of the drug depends on its concentration at the site of action                          
[32, 33]. This, in turn, depends on the solubility and stability of the drug in aqueous media. 
Therefore, the drug must be soluble in appropriate solvents and it is very important that it does 
not precipitate in the aqueous environment (or at physiological conditions) and that it is stable 
(not degradable) in the timescale of the biochemical studies [34-36]. 
Upon entering the cell, the drug needs to reach the target or interact / interfere with the relevant 
cellular processes. Radical and reactive oxygen species (ROS) are related with many diseases 
such as inflammation, hypertension, coronary heart disease, atherosclerosis, Alzheimer's 
disease, Parkinson's disease etc. [37]. These free radicals are produced under certain 
environmental conditions and during normal cellular functions in the body. So, antioxidants 
play an important role to protect the human body against damage by radicals [38]. 
Consequently, evaluation of antioxidant activity of new compounds is desirable. 
Many biological targets including, membranes, proteins and DNA have been used for 
evaluation of biological activities of compounds [39]. The anticancer activity of cisplatin is 
believed to result from its interaction with DNA. The drug reacts with nucleophilic sites in 
DNA forming monoadducts, as well as intra and inter strand crosslinks. This has been used as 
rationale to choose DNA as biological target to evaluate the anticancer activity of other metal 
complexes [40]. DNA regulates many biochemical processes that occur in the cellular system. 
The different loci present in the DNA are involved in various regulatory processes such as gene 
expression, gene transcription, mutagenesis, carcinogenesis, etc. Transition metal complexes 
can bind to DNA by both covalent and non-covalent interactions. Covalent binding involves 
the coordination of the nitrogenous base or the phosphate moiety of the DNA to the central 
metal ion. The non-covalent binding modes are intercalation, which involves the stacking of 
the molecule between the base pairs of DNA, groove binding, which comprises the insertion 
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of the molecule into the major or minor grooves of DNA and electrostatic or external surface 
binding [5, 41]. Among these, covalent binding and intercalation are among the most important 
DNA binding modes for therapeutic drugs. The DNA binding mode and strength of the affinity 
are affected by several factors, such as planarity of ligands, the coordination geometry, the 
ligand donor atom type, the metal ion type and its flexible valence [5, 41, 42]. 
1.8 Objectives 
The main objective of the current work is to develop drugs to fight cancer and microbial 
diseases. Herein, we report the synthesis, characterization and solution behavior of zinc 
complexes with two ligands: an S-methyl dithiocarbazate Schiff base and 4-methyl-2,6-
bis(pyridin-2-yl-hydrazonomethyl)-phenol. Stability in aqueous media and evaluation of 
antioxidant activity of the synthesised compounds are reported. The BSA and DNA binding 
ability of the zinc(II) complexes are also evaluated and discussed. The biological screening 
focused on their cytotoxic, antibacterial and antifungal activity. 
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2. Experimental  
2.1 Materials and reagents 
2,6-Diformyl-4-methylphenol, 2-hydrazino pyridine (from Sigma-Aldrich), S-methyl 
carbazate and Zn(CH3COO)2.2H2O (from Panreac) were used as supplied. Solvents such as 
ethanol, methanol (from Carlo Erba), DMSO (from Fisher Scientific), D2O, DMSO-d6 (from 
Euriso-top) were used. Phosphate buffered saline (PBS) was purchased from Sigma-Aldrich as 
tablets readily soluble in water (deionized water) giving 0.01 M in phosphate (NaCl, 0.138 M; 
KCl, 0.0027 M), pH 7.4 at 25 ºC. Defatted BSA (Sigma-Aldrich reference A-7511; ≥ 97 %) 
with molecular weight of 66,430 Da and calf thymus DNA (ctDNA) were purchased from 
Sigma-Aldrich. Millipore® water was used in the experiments with biological molecules. All 
other materials not mentioned here were either analytical or reagent grade. 
2.2 Instrumentation 
Elemental analysis for C, H, N and S were carried on a FISONS EA 1108 CHNS-O apparatus 
at Laboratório de Análises of Instituto Superior Técnico. The NMR spectra were recorded at 
ambient temperature on a Bruker Avance II + 300 (Ultra Shield TM Magnet) spectrometer 
operating at 300.13 MHz. The 1H NMR chemical shifts are reported in ppm using TMS 
(tetramethylsilane) as internal reference or the solvents’ residual peak. The Infra-Red (FT-IR) 
spectra were recorded on Alpha RTDLaTGS HR 0.8 FTIR spectrophotometer and the UV-
Visible absorption spectra were recorded on a Perkin Elmer Lambda 35 UV-Vis 
spectrophotometer with 10.0 mm optical path cuvettes. A 500-MS Varian Ion Trap Mass 
Spectrometer was used to measure ESI-MS spectra of methanolic solutions of the ligands and 
complexes in both positive and negative modes. Circular dichroism spectra were recorded on 
a JASCO J-720 spectropolarimeter (JASCO, Hiroshima, Japan) with UV-Vis (500 – 200 nm) 
photomultiplier (EXEL-308) at room temperature with a 10 mm quartz cell. The spectra were 
acquired at scanning speed of 200 nm/min; band-width of 2.0 nm; response of 2.0 sec; 
sensitivity of 100 mdeg and data pitch of 2 nm. Three accumulations were made for each 
measurement and the average was taken. Fluorescence measurements were carried out on a 
SPEX® Fluorolog spectrofluorimeter (Horiba Jobin Yvon) in a FL3-11 configuration, equipped 
with a Xenon lamp and in a 10 mm quartz cuvette. The instrumental response was corrected 
by means of a correction function provided by the manufacturer. The experiments were carried 
out at room temperature and all are steady-state measurements. 
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2.3 Synthesis of the ligands  
4-methyl-2,6-bis(pyridin-2-yl-hydrazonomethyl)-phenol – L1 - A methanolic solution (43 
mL) of 2-hydrazino pyridine (0.4651 g, 4.26 mmol) was added dropwise to a methanolic 
solution (32 mL) of 2,6-diformyl-4-methylphenol (0.3501 g, 2.13 mmol) with constant stirring 
for 30 min at room temperature. The mixture was refluxed for    5 h, cooled to room temperature 
and filtered. The yellow microcrystalline solid was collected, washed thoroughly with cold 
methanol and dried in vacuum. Yield: 74% (0.5436 g). ESI-MS (MeOH) m/z [calculated 
(Found)]: 347.16 (347.11) (100%) [L1+H]+. Elemental analysis; C19H18N6O.0.5 H2O; C, 64.21%; 
H, 5.39%; N, 23.65%. Found: C, 64.54%; H, 5.10%; N, 23.53%. FT-IR (KBr, cm-1): 3411 (OH), 
3194 (NH), 1599 (C=N). 1H NMR (300 MHz, DMSO-d6, δ(ppm)): 2.31 (s, 3H, C7-H), 6.80 (t, 
2H, C14 & 24 -H), 7.07 (d, 2H, C12 & 26 -H ), 7.42 (s, 2H, C3 & 5 -H), 7.68 (t, 2H, C13 & 25 -H), 
8.17 (d, 2H, C15 & 23 -H), 8.33 (s, 2H, C14 & 24 -H), 11.05 (s, 2H, N-H), 11.71 (s, 1H, O-H). 
13C NMR (300MHz, DMSO-d6, δ(ppm)): 20.10 (C7), 121.14 (C2 & 6), 128.34 (C4), 138.47 (C15 
& 23), 148.00 (C8 & 18), 152.87 (C1), 156.72 (C11 & C21). UV-Vis [DMSO, λmax/nm (ε/M-1cm-
1)]: 369 (7.17x104), 345 (1.53x105), 331 (1.47x105). 
 
Scheme 3 Synthesis of L1. 
Methyl-phenol-di-S-methyl dithiocarbazate - L2 - A methanolic solution (4 mL) of                            
S-methyl carbazate (0.3918 g, 4.34 mmol) was mixed with a methanolic solution (12 mL) of                   
2,6-diformyl-4-methyl phenol (295.7 mg, 1.80 mmol) with stirring. The mixture became 
cloudy and a yellow solid formed. It was refluxed for 4 h, cooled to room temperature and a 
yellow solid was filtered, washed with methanol followed by petroleum ether and dried in 
vacuum. Yield: 78% (0.5251 g).  ESI-MS (MeOH) m/z [calculated (Found)]: 371.55 (371.03) 
(100%) [L2-H]-. Elemental analysis; C13H16N4OS4.1.5H2O, C, 39.08%; H, 4.79%; N, 14.02%, S, 
32.10. Found: C, 39.32%; H, 4.06%; N, 13.70%, S, 32.24. FT-IR (KBr, cm-1): 3119 (OH), 2982 
(NH), 1617 (C=N), 1518 (C=C), 1320 (C-O), 1044 (C=S), 770 (C-S). 1H NMR (300MHz, 
DMSO-d6, δ(ppm)): 2.33 (s, 3H, C7-H), 2.59 (s, 6H, C14 & C22 -H), 7.57 (s, 2H, C3 & C5 -H), 
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8.53 (s, 2H, C8 & C6 -H), 10.81 (s, 1H, O-H), 13.52 (s, 2H, N-H).
 13C NMR (300MHz, DMSO-
d6, δ(ppm)): 16.81 (C14 & 18), 19.79 (C7), 119.65 (C2 & 6), 129.61 (C4), 131.31 (C3 & 5), 144.75 
(C8 & 16), 154.54 (C1), 197.45 (C11 & 19). UV-Vis [DMSO, λmax/nm (ε/M-1cm-1)]: 371 (1.07x105), 
345 (1.53x105), 332 (1.46x105). 
 
 
 
 
 
 
Scheme 4 Synthesis of L2. 
2.4 Synthesis of complexes 
[Zn2(L1)(OAc)3] (C1) - An ethanolic solution (3 mL) of Zn(CH3COO)2.2H2O (228.7 mg, 1.04 
mmol) was added dropwise to a solution of L1 (181.1 mg, 0.523 mmol) in ethanol (32 mL) 
with constant stirring for 30 min at room temperature. The mixture was refluxed for 2 h, and 
then cooled to room temperature. Finally, an orange coloured compound was separated from 
the reaction mixture, washed thoroughly with petroleum ether and dried in vacuum. Yield: 50% 
(0.1693 g). ESI-MS (MeOH) m/z [calculated (Found)]: 409.08  (409.31) (100%) Zn(L1)+,  
266.0  (266.12)  (20%) Zn2(L1)(OAc)
2+. Elemental Analysis for C25H26N6O7Zn2.H2O; C, 44.57%; 
H, 4.23%; N, 12.47%. Found: C, 44.42%; H, 4.17%; N, 12.97%. FT-IR (KBr, cm-1): 3012 (NH), 
1629 (C=N), 1560 (C=C), 772 (C-H), 673 (Zn-O), 479 (Zn-N). 1H NMR (300 MHz, DMSO-
d6, δ(ppm)) 2.23 (s, 3H, C7-H), 6.54 (t, 2H, C14 & 24 -H), 6.62 (d, 2H, C12 & 26 -H ), 7.10 (s, 2H, 
C3 & 5 -H), 7.51 (t, 2H, C13 & 25 -H), 7.80 (d, 2H, C15 & 23 -H), 8.20 (s, 2H, C14 & 24 -H) 
 
Scheme 5 Synthesis of C1. 
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[Zn2(L2)(OAc)]  (C2) - Complex C2 was synthesized in a similar procedure as the one used for 
C1, with L2 (166 mg, 0.446 mmol) instead of L1, where a yellow coloured compound 
separated out from the reaction mixture which was filtered, washed thoroughly with petroleum 
ether and dried in vacuum. Yield: 57% (0.1732 g). ESI-MS (MeOH) m/z [calculated (Found)]: 
198.15 (98.58) (40%) (Zn(L2)H3
3+, 496.86 (497.09) (2%) Zn2(L2)
+, 434.94  (434.29) (10%) 
Zn(L2)H+. Elemental Analysis for  C16H20N4O4S4Zn2; C, 32.50%; H, 3.41%; N, 9.47%, S. 
21.68 Found: C, 32.48%; H, 3.14%; N, 9.75%, S, 21.31. FT-IR (KBr, cm-1): 2920 (NH), 1618 
(C=N), 1548 (C=C), 1317 (C-O), 965 (C-S), 772 (C-H), 673 (Zn-O). 1H NMR (300 MHz, 
DMSO-d6, δ(ppm)) 2.23 (s, 3H, C7-H), 6.54 (t, 2H, C14 & 24 -H), 6.62 (d, 2H, C12 & 26 -H ), 7.10 
(s, 2H, C3 & 5 -H), 7.51 (t, 2H, C13 & 25 -H), 7.80 (d, 2H, C15 & 23 -H), 8.20 (s, 2H, C14 & 24 -H)
 
 
 
Scheme 6 Synthesis of C2. 
2.5 Stability studies in aqueous medium 
The stability of the Zn(II) complexes was evaluated using UV-Vis and NMR spectroscopies. 
UV-Vis absorption experiments were done using final concentrations of 25 μM (DMSO, 3% 
v/v) in PBS buffer (10 mM, pH 7.4) in the absence and presence of bovine serum albumin 
(BSA, 25 μM). The UV-Visible spectra (250-600 nm) were recorded for six consecutive hours 
and the spectra were measured again after 24 hours. Stability of complex C1 (25 µM, 2% 
DMSO v/v) was also followed in cell culture medium with and without FBS (10 % v/v). The 
UV-Visible spectra (250-600 nm) of the complex were recorded for six hours and measured 
again after 24 hours. The stability study of complex C1 was also carried out by 1H NMR. 12.5 
mg of C1 were dissolved in 250 μl of DMSO-d6. Then, 20 μl of this solution were mixed with 
380 μl of the phosphate buffer giving 5 % DMSO and 95 % D2O. Finally, the stability of the 
compound was studied for 24 h by 1H-NMR spectroscopy. 
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2.6 BSA binding studies  
Stock solutions of BSA were prepared in buffer solution (PBS, 10 mM, pH 7.4 at 25ºC) and 
kept overnight to hydrate. The concentration of BSA stock solutions ranged from ca. 34 to 918 
µM, which was estimated considering the molar extinction coefficient (279 nm, 44,309 M-1 
cm-1) [43]. The concentration of stock solutions of Schiff base ligands and complexes was 
between ca. 100 to 5370 µM which were prepared by dissolving the compounds in 
spectroscopic DMSO.  
2.6.1 UV–visible spectroscopic titrations  
Electronic absorption titrations were performed by successive additions of BSA stock 
solutions, ca. 750 - 900 μM, to solutions of compounds in 4% (v/v) of DMSO-PBS (10 mM, 
pH 7.4) where a similar volume of BSA was also added to the reference cell. The initial 
concentration of compounds was set at ca. 25-29 μM and the molar ratio of BSA to compound 
varied between 0 and 4. The absorption spectra were recorded from 270 to 700 nm at room 
temperature. All the experiments were performed in phosphate buffer saline (10 mM, pH 7.4) 
in a conventional quartz cell (10.0 mm).  
2.6.2 Circular dichroism spectra 
To evaluate the structural changes of BSA induced by the addition of compounds, circular 
dichroism (CD) spectra were measured in solution. The technique is  appropriate because BSA 
has a high percentage of α-helical structure, which shows a characteristic CD signal in the Far-
UV region. Predominately α-helical proteins show two strong negative bands with maxima at 
209 and 220 nm. Changes in the intensity of these bands reflect changes in the amount of 
helicity of BSA [44]. Stock solutions of protein (34.12 - 100 µM) were prepared in buffered 
solutions (PBS, 10 mM, pH 7.4). Spectral changes of BSA were monitored after adding 
different concentrations of compounds (0 –3 μM) to the BSA solution.  
2.6.3 Spectrofluorimetric titrations  
Working solution of BSA was obtained by diluting stock solution to a concentration of 1.16 
μM (for L1, L2 and C1 assays) and 1.25 μM (for C2 assay) in PBS buffer with final volume 
of 2520 μl in 10 mm path length quartz cuvette. The intrinsic fluorescence emission quenching 
experiments of BSA were done by successive additions of the compounds to obtain final 
concentrations ranging from 0.20 - 5.81 μM with DMSO < 5% v/v, where individual working 
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solutions were prepared to obtain molar ratios of BSA: Compounds ranging from 1:0 to 1:6. 
All spectra were recorded by allowing solutions to equilibrate after every addition of the 
compounds. The fluorescence emission spectra were recorded between 295 and 400 nm by 
exciting at 285 nm (λex = 285 nm) with slits of 3 nm. UV-visible absorption spectra were 
recorded for each sample to correct the absorption and inner filter effects of the fluorescence 
emission intensities. All spectra were collected in the S/R mode and corrected for optics and 
detector wavelength dependence. Moreover, blank assays were done for each system where the 
fluorescence spectra for solutions containing the same concentration of compound without 
BSA were recorded and subtracted from the corresponding emission spectra containing the 
fluorophore.  
Successive additions of the compounds under the same conditions cause fluorescence 
quenching, a decrease in the emission fluorescence intensity of BSA at emission max                  
(λmax = 340 nm), and the fluorescence quenching can be analysed by the Stern-Volmer equation 
(Equation 1) [45].  
F0/F = 1+Ksv[Q] = 1+Kqτ0[Q]     (1) 
where F and F0 are BSA fluorescence intensities in the presence and absence of quencher 
(metal complexes), respectively. Kq, Ksv, τ0 and [Q] are the quenching rate constant, the Stern-
Volmer quenching constant, the average biomolecule lifetime in the absence of quencher and 
the quencher concentration, respectively.  
2.7 DNA interaction studies 
All the experiments involving the interaction of ligands and complexes with ctDNA were 
carried out in buffered solution (PBS, 10 mM, pH 7.4) at room temperature. Stock solutions of 
DNA were prepared by dissolving the nucleic acid in buffered solution (PBS, 10 mM, pH 7.4 
at 25ºC), keeping it at 4ºC for about 2 days to allow dissolution of the DNA and used within a 
week. The concentration of the prepared ctDNA stock solutions were calculated based on their 
absorbance at 260 nm by using their per nucleotide extinction coefficient ε260 = 6600 M-1 cm-1 
[46]. Solutions of DNA gave ratios of absorbance A260/A280 of ca. 1.9, indicating that the DNA 
was sufficiently pure and free of protein [46].  
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2.7.1 UV-Vis spectroscopy  
Stock solutions of both ligands and complexes were prepared in DMSO with concentration of 
2.65 and 1.54 mM for ligands L1 and L2, respectively; and 1.53 mM for C1 and C2. Then 
further dilutions were made in PBS buffer (pH 7.4 10 mM) having final concentrations of ca. 
37.8 μM for L1 and ca. 25 μM for L2 and complexes. Absorption titration experiments were 
performed by maintaining the compounds’ concentration roughly constant and increasing the 
concentration of DNA to obtain ratios of [compound]/[DNA] ranging from 1:0 to 1:2.4 for L1 
and from 1:0 to 1:4 for the rest of the compounds. To eliminate the contribution of the 
absorbance of ctDNA itself, an equal quantity of ctDNA was added to both the sample and the 
reference solutions. All solutions were incubated for 4 - 5 min before absorption spectra were 
recorded. The titration kept going until there were no changes in the spectra, indicating that 
binding saturation was achieved. 
2.7.3 Circular dichroism spectra 
Circular dichroism (CD) is a useful technique for monitoring DNA conformational changes 
resulting from changes in environmental conditions, such as temperature, ionic strength, and 
pH, and for the study of the interaction between DNA and compounds. Circular dichroism 
studies were done in quartz SUPERASIL© cuvettes of 10 mm optical path. The ctDNA solution 
was prepared by dilution of the stock solution (2.56 mM) in PBS buffer (pH 7.4, 10 mM) to 
obtain a final concentration of ca. 60 μM in each sample. Stock solutions of ligands and                     
Zn-complexes, ca. 5.7 mM in DMSO were prepared. Spectra were recorded by keeping the 
concentration of DNA constant while varying the concentration of ligands and complexes from 
0 to 260 μM to obtain DNA: compound ratios ranging from 1:0 to 1:4.5. After every addition, 
the samples were allowed to equilibrate for a few minutes before spectral measurements. PBS 
buffer solution was used to obtain the baseline, which was subtracted from each CD spectrum. 
The spectra were collected from 200 - 500 nm with a resolution of 1.0 nm, with band-width of 
1.0 nm, scan speed of 200 nm/min, 2.0 s response time and 3 accumulations were taken and 
averaged. The recorded spectra (in millidegrees) were converted into Δε expressed in M-1cm-1 
using the concentration of ctDNA and the cell path length (1 cm). The processing of the CD 
spectra was done using JASCO32 software. 
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3. Results and Discussion 
In this work zinc complexes of Schiff bases 4-methyl-2,6-bis(pyridin-2-yl-hydrazonomethyl)-
phenol (L1) and methyl-phenol-di-S-methyl dithiocarbazate (L2) were prepared and studied. 
The Schiff base ligands were synthesized by condensation of an aromatic dialdehyde with 2-
hydrazino pyridine and S-methyl dithiocarbazate in methanol at refluxing temperature for 4-5 
h to yield L1 and L2, respectively. Complexes were prepared from the reaction of zinc acetate 
with the Schiff bases in methanol/ethanol at room temperature for 15-30 min and then at 
refluxing temperature for 2 h. Percentage yields of the reactions ranged from 74 – 78% for the 
Schiff bases and 49 – 56% for the zinc complexes. All synthesized compounds were soluble in 
DMSO.  
Upon complexation of the metal ion with S-substituted dithiocarbazate derived Schiff base 
ligand, deprotonation of the nitrogen of the dithiocarbazate is expected, leading to an 
iminothiolate and coordination via NS atoms is anticipated.  
3.1 Characterization 
To confirm the formation of the metal complexes and to characterize them, several techniques 
were employed. The proposed structures and stoichiometries were initially established by 
elemental analysis and mass spectrometry. The analytical data for ligands and metal complexes 
agreed well with the formulations proposed. All the mass spectra show signals corresponding 
to the molecular weight of either the protonated complexes or adducts formed with solvent 
molecules. Elemental analysis and various spectroscopic characterization results are discussed 
in the following sections. 
NMR spectroscopy is very important to determine the groups through which the ligands form 
their corresponding metal complexes and confirm the proposed structures. 1H and 13C NMR 
experiments were done for all ligands and zinc complexes. 1H NMR spectra were recorded at 
room temperature using DMSO-d6 as solvent and the chemical shifts are given in Tables 1 and 
3, whereas 13C NMR data is given in Tables 2 and 4. 1H NMR spectroscopy allowed the 
identification and attribution of the peaks making a perfect correspondence both in the chemical 
shift and integration values to the proposed structures depicted in Figure 6. An important peak 
assignment is the one corresponding to the azomethine protons (HC=N), which clearly 
confirms the formation of the Schiff bases [49 - 52]. 
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                                         L1               L2 
                      
          
Figure 6 Structure of Schiff base ligands and complexes synthesised with the atom labelling   
               scheme used in the NMR characterization. 
The 1H NMR spectra of the Schiff base ligands show a broad peak ranging from                                   
10.81-11.71 ppm attributed to phenolic hydroxyl protons [48 - 50]. The absence of this peak in 
the spectra of complexes C1 and C2 confirms the involvement of deprotonated hydroxyls in 
chelation to the metal ion [50, 51]. The peaks displayed by 1H NMR spectra of Schiff bases in 
the range δ = 8.33–8.53 ppm were attributed to the azomethine protons (HC=N) [48 - 51]. The 
spectra of the complexes exhibited the azomethine proton signals shifted downfield which 
confirms the formation of the metal complex, with binding through these donors [50, 51].  
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Signals of aromatic protons were observed in the chemical shift range 6.80–8.17 ppm and 
aliphatic protons showed up at 2.31 ppm [52]. The signals of 13C NMR assigned to the chemical 
shift of methyl groups for the two ligands were observed at 16.81 and 20.10 ppm [53], while 
the signals of aromatic carbons were in the range of 119.65–156.72 [53, 54]. The signals 
observed at 145.75 and 148.00 ppm, were attributed to the chemical shifts of azomethine 
carbons, which confirm the formation of the Schiff bases [55, 56]. 
Table 1 1H NMR chemical shifts ( /ppm) and assignment for L1 and C1 in DMSO-d6. 
Compound                /(multiplicity, number of protons) 
      H14 &24     H12 & 26           H3 & 5        H13 & 25    H15 & 23      HC=N       Ar-OH 
L1      6.8 (t, 2H)   7.1 (d, 2H)       7.4 (s, 2H)           7.7 (t, 2H)         8.2 (d, 2H)      8.33 (s, 2H)    11.05 (s, 1H)  
C1           6.5 (t, 2H)   6.6 (d, 2H)       7.1 (s, 2H)          7.5 (t, 2H)         7.8 (d, 2H)      8.21 (s, 2H)        - 
 
Table 2: 13C NMR chemical shifts (/ppm) and assignment for L1 and C1 in DMSO-d6.  
Compound                                                               /(ppm of 13C) 
      C2 & C6    C4              C15 & C23         C8 & C18              C11 & C21 
L1                  121.14            128.34                 138.47                  148.00                    156.72     
C1                       125.03            125.03                 145.37                  156.76                    162.13 
 
 
Table 3 1H NMR chemical shifts ( /ppm) and assignments for L2 and C2 in DMSO-d6. 
Compound                                       /(multiplicity, number of protons) 
         H14 & 22          H3 & 5            -NH                Ar-OH          HC=N 
L2   2.59 (s, 6H)         7.57 (s, 2H)          13.52 (s, 2H)    10.81 (s, 1H)       8.33  (s, 2H) 
C2         3.28 (s, 6H)         7.41 (s, 2H)                -                     -                        8.68 (s, 2H) 
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Table 4 13C NMR chemical shifts ( /ppm) and assignment for L2 and C2 in DMSO-d6. 
Compound                                                               /(ppm of 13C) 
      C14 & C22                       C2 &C6              C3 & C5                  C8 & C16       
L2                  16.8                                   119.7                   131.3                       144.8                   
C2                       14.7                                   120.7                  139.8                       160.4                   
The aromatic protons and carbons of ligands in the 1H and 13C NMR spectra appear around 
6.8-8.2 ppm and 119.7-156.7 ppm, respectively, which were shifted to 6.5- 7.8 ppm and                     
120.0-162.13 ppm, respectively, in the Zn(II) complexes.  
a) 
 
 
b) 
L1 
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Figure 7 Aromatic region of the 1H NMR spectra of (a) L1 and (b) C1 in DMSO-d6 at room 
temperature. 
The electronic absorption spectra of the ligands and their metal complexes in DMSO were 
scanned in the region 270 – 700 nm at concentrations of 25 μM and the results are depicted in 
Fig. 8. In the spectra of the Schiff base ligands it was possible to observe two set of bands 
corresponding to the π → π* and n → π* transitions of imine bonds present in the molecules 
[56]. The ligands exhibited high intensity bands which appeared at wavelengths of ca. 330 and 
380 nm which were assigned to π→π* and n→π* transitions, respectively. For metal 
complexes, the first band at ca. 310 - 370 nm corresponding to the π→π* transition was 
observed, whereas the second intra-ligand band at higher wavelength ca. 430 - 480 nm ascribed 
to n→π* band showed either a blue shift with a reduction of intensity or disappeared. This is 
due to donation of the lone pair of electrons to the metal and hence the coordination of the 
azomethine group [57]. Both of Zn(II) complexes showed the presence of ligand-to-metal 
charge transfer (LMCT) band (400 - 450 nm). 
C1 
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Figure 8 UV-Visible absorption spectra for Schiff base ligands and their corresponding     
                Zinc complexes in DMSO at room temperature. 
 
The ligands and complexes were also characterized by electrospray ionization mass 
spectrometry (ESI-MS) and it was possible to assign the peak corresponding to the molecular 
ion for both ligands, according to the expected molecular weight [58], as shown in Table 5. 
The complexes are very hard to ionize and only a few peaks were assigned. 
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Table 5 Assignment of ESI-MS peaks for Schiff base ligands and their corresponding   
             zinc(II) complexes. 
Species              m/z (%) 
Theoretical            Found 
L1+H+                                                                                            347.16  347.11(100%) 
L2-H-                                          371.55  371.03(100%) 
Zn(L2)H3
3+                                                           198.15            98.58 (40%) 
Zn(L1)+                 409.08           409.31(100%) 
Zn2(L1)(OAc)
2+                 266.0  266.12 (20%)  
Zn2(L2)
+                  496.86       497.09(2%) 
Zn(L2)H+                  434.94 434.29(10%) 
 
The nature and functional groups attached to metal atoms can be provided by FTIR spectra. 
The IR spectra of zinc complexes were compared with that of corresponding Schiff base 
ligands where changes that have taken place during complexation are a confirmation for 
formation of the complexes. The complexes exhibited IR bands approximately around 3447 
cm-1 due to ν(OH), which refer to water molecules present in the complexes lattice. Upon 
complexation, the band of the azomethine group which in the of free ligands appeared at 
1599 and 1617 cm−1 (in L1 and L2, respectively) shifted to 1629 and 1654 cm−1 for C1 and C2 
respectively, indicating the coordination of the azomethine nitrogen atom to the metal ion. 
Furthermore, the coordination is further confirmed by appearance of new bands around 680-
684, 519 - 580 and 471 - 502 cm-1 due to ν(Zn-N), ν(Zn-O) and ν(Zn-S), respectively. Other 
bands like ν(C-H)Ar and ν(C=C) appear around 3050 cm-1 and 1490 cm-1, respectively [59, 60]. 
Characteristic infrared bands of the Schiff base ligands and their complexes are listed in                
Table 6 together with their assignments.  
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Table 6 IR spectral assignments (cm-1) of ligands and complexes. 
Compound                                                               ν/(cm-1) 
      OH             N-H       C=N         Zn-N     Zn-O  
L1               3441            3194      1599          -     - 
L2               3119             2982          1617          -     - 
C1                        -                3012          1629          673   670 
C2                        -            3177         1654          682   596 
 
Elemental analysis data on the percentage of carbon, hydrogen and nitrogen in all ligands and 
complexes were fairly in agreement with calculated values for the proposed structures as shown 
in the Table 7. Both Zn-complexes contain two Zn ions per ligand molecule. In C1 three 
molecules of acetate are present probably coordinated to the Zn atoms, and in C2 only one. 
Solvation molecules of water and/or MeOH are also present in the isolated solids. These 
findings/formulations are corroborated by the NMR studies, which show equivalence between 
both halves of the molecules.  
 
Table 7 Analytical data for Schiff base ligands and their corresponding Zn(II) complexes. 
Compound                                       Elemental Analysis calculated (found) (%) 
    C      H          N             S  
L1        64.21 (64.5)  5.39 (5.1)    23.7 (23.5)                    - 
L2       39.1 (39.3)       4.8 (4.10)          14.0 (13.7)               32.1 (32.2)     
C1       45.34 (45.96)    4.11 (4.01)    12.69 (12.86)     - 
C2                         32.50 (32.37)  3.41 (3.14)    9.47 (9.77)           21.68 (21.31) 
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3.2 Stability studies in aqueous medium  
Since biological studies are typically done in aqueous media at physiological pH, in order to 
proceed with studies with biological molecules, it is necessary to ensure that the complexes do 
not precipitate in the aqueous environment, and that they are stable in the timescale of the 
studies. Thus, the stability of the Schiff base ligands and complexes was evaluated with                
UV-vis spectroscopy in pH 7.4 buffered solutions containing a minimum amount of organic 
solvent, which is used to dissolve the compounds. Phosphate Buffer Saline (PBS) was chosen 
due to its composition, since the osmolarity and ion concentrations of the solution match 
closely those of the human body. Changes observed with time for each ligand and complex 
solution were followed with UV-vis spectroscopy using 5% of DMSO and 95% PBS. Except 
for a slight decrease in absorbance values due to precipitation, the ligands, L1 and L2 and 
corresponding complexes C1 and C2 spectra maintain their original form. It was observed that 
the stability in aqueous media increased upon formation of the complexes. Overall no 
significant changes were observed in the complexes’ spectra as seen in Fig. 9. 
Observed changes may be due to low solubility of the complexes in the aqueous media and 
therefore if lower concentrations are used in the assays with biological molecules both the 
stability and the solubility are not compromised. Therefore, it can be assumed that synthesised 
compounds are found to be stable in the physiological environment to undergo necessary 
reactions required for bioactivity. 
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Figure 9 UV-Vis absorption spectra of C1 (A) and C2 (B) measured with increasing time (for 6 
consecutive hours and again after 24h) for solutions containing 25 μM for each complex in 
PBS buffer with 3% DMSO. Inset: Variation at maxima (λ= 296 nm, 296 nm and 422 nm for 
C1, and λ= 390 nm and 465 nm for C2) in the first 400 minutes  
Stability of complex C1 (25 µM, 3%DMSO) was also followed in cell culture medium. The 
UV-Visible spectra (250-600 nm) of the complex, which were recorded for six consecutive 
hours and again after 24 hours (Fig. 10), show that the complex is stable in this medium 
although there is a decrease in absorbance due to precipitation. 
 
 
 
 
 
 
 
 
Figure 10 UV-Vis absorption spectra of C1 measured with increasing time (for 6 consecutive hours   
and again after 24h) for solutions containing 25 μM for the complex in cell culture medium 
with 3% DMSO.  Inset: Variation at maxima (λ= 296 nm, 350 nm and 422 nm) in the first 
400 minutes.  
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1H NMR spectroscopy was also used to study the stability of C1 in D2O monitoring the 
1H 
NMR for 3 h and finally after 24 h. It was apparent from the measured spectra that the 
compound is stable in aqueous solution without hydrolysis except a simple shift of the peak at 
8.25 to 7.7-7.8 due to the addition of D2O. The proton integrations show that in the aromatic 
region there are still 6 protons making up a total of 12  protons as shown in the Fig. 11.  
 
Figure 11  1H NMR spectra of C1 in DMSO-d6:D2O, 5:95 %(v/v) measured with time. 
3.3 Interaction with biomolecules 
3.3.1 UV–visible BSA titrations   
UV–visible absorption spectroscopy is a simple, useful technique to investigate conformational 
changes of proteins, even at low concentrations. This method is applicable to knowing the 
change in hydrophobicity [60] and the interaction between a drug and proteins [61].  Fig. 12 
show the electronic absorption spectra of the compounds in the absence and presence of 
increasing concentrations of BSA where the ratio of [BSA]/[compound] varied from 0.0 - 4.0 
in buffered solution (PBS, 10 mM pH 7.4). The maximum absorption of the compounds 
exhibited a slight hypsochromic shift (hyperchromic for C2) in general by the incremental 
addition of BSA. These changes indicate that the compounds change its environment in the 
presence of BSA suggesting binding between the two.    
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Figure 12 UV-visible absorption spectra of (A and B) 2.5 x 10-5 M L1 and C1 in the absence and 
presence of 0, 5.3, 12.6, 24.54, 36.15 and 47.77 µM of BSA; (C) 2.8 x 10-5 M L2 in the 
absence and presence of 0, 5.5, 13.5, 27.1, 40.0 and 52.6 µM of BSA; (D) 2.9 x 10-5 M C2 
in the absence and presence of 0, 12.86, 25.28, 37.27, 48.87 and 60.07 µM of BSA in 
buffered solution (10 mM, PBS pH 7.4) 
3.3.2 Circular dichroism spectroscopy  
Circular Dichroism (CD) spectroscopy is recognized as an important technique to explore the 
conformational alteration of the secondary structure of proteins [46]. To determine the 
structural changes of BSA by the addition of Schiff base complexes, we measured the CD 
spectra to investigate possible conformational changes of serum albumins in solution. The 
technique is appropriate because BSA has a high percentage of α-helical structure, which shows 
a characteristic CD signal in the far-UV region [35].  It is worthwhile to note that the studied 
ligands and complexes do not possess any CD spectra under the investigated wavelength range 
200-280 nm, or any other, as they are not chiral. Here the spectra are solely due to the protein 
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and characterized by two negative bands at 210 and 220 nm due to π→π* and n→π* transitions 
in the peptide bonds of  -helix, respectively [47]. The effect of the complexes on the secondary 
structure of the protein was studied by keeping the concentration of BSA at 1 × 10−6 M while 
varying the concentration of Schiff base complexes C1 and C2, in a buffer solution (10 mM 
PBS, pH 7.4) up to 3:1 molar ratio of compound: BSA as shown in Fig. 13. 
Upon addition of the Schiff base metal complexes, the CD spectra of the protein undergo a 
gradual decrease in band intensity of both negative bands without any significant shift of the 
peak positions. This phenomenon indicates the progressive reduction of the -helical content 
due to interaction with the probes. The effect is stronger for complex C1 than C2. 
  
Figure 13 CD spectra of BSA in the absence and presence of increasing concentrations of C1   
                 and C2.  [BSA] = 1.0 × 10−6 M where the concentration ratios of  BSA: compounds   
                 (a–f) were: 1:0; 1:0.5; 1:1; 1:1.5; 1:2; and 1:3. 
3.3.3 Fluorescence quenching  
Albumin is a water-soluble protein, which is crucial for many living organisms. The significant 
role of transporting essential trace metal ions, metal complexes, and drugs in the circulatory 
system is played by albumin [62, 63]. One useful technique to study binding of a compound to 
albumin is fluorescence. Protein fluorescence is generally due to three amino acids, 
namely tyrosine (Tyr), tryptophan (Trp-134, located on the surface of domain IB, Trp-212 
located in the hydrophobic pocket of domain IIA) and phenyl alanine (Phe) residues. Thus, 
BSA fluorescence emission spectra were recorded in the absence and presence of increasing 
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concentrations of complexes to investigate its binding to BSA. BSA solutions show strong 
fluorescence emission having its maxima at 345 nm upon excitation at 285 nm, which is 
associated with tryptophan residues, (Fig. 14). The fluorescence intensity was strongly 
quenched upon increasing the Schiff base ligands and complex concentration whereas no 
changes were observed in the position of the emission maximum wavelength and peak shape. 
As a result, we can conclude that the complexes bind BSA, which results in conformational 
changes in the secondary structure of the protein and quenching of its intrinsic 
fluorescence [64]. 
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Figure 14   Fluorescence emission spectra of BSA in absence and presence of different   concentrations 
of C1 (A) and C2 (B) at room temperature where [BSA] = 1.25× 10−6 M and [compound] 
varied from 0 – 5.8 × 10−6 M (for C1) and 0 – 4.81 × 10−6 M (for C2). Arrows show 
changes upon increasing complexes concentration. Inset: Stern-Volmer plots of F0/F vs. 
[Complex]. 
The mechanism by which collisional encounters between the fluorophore and quencher take 
place is referred to as quenching. There are two main methods for BSA fluorescence 
quenching; static and collisional or dynamic quenching, which are a valuable source of 
information regarding binding between the fluorescent sample and the quencher. The 
quenching can be described by the linear Stern–Volmer equation. 
F0/F = 1+Ksv[Q] = 1+Kqτ0[Q]     (1) 
Where F and F0 are BSA fluorescence intensities in the presence and absence of quencher 
(metal complexes), respectively. Kq, Ksv, τ0 and [Q] are the quenching rate constant, the Stern-
Volmer quenching constant, the average biomolecule lifetime in the absence of quencher and 
the quencher concentration, respectively. Ksv values at 298 K were found to be in the range of 
104 - 105 M−1 (see Table 8). These constants indicate that BSA has high binding affinity for 
these compounds. The Kq values, were calculated considering τ0= 10−8 s, [65] and are all greater 
than the maximum scatter collision quenching constant of quenchers with BSA 
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(2 × 1010 M−1 s−1) [66] suggesting a static quenching mechanism [67], resulting from the 
formation of an adduct between the protein and the Zn-complexes. 
Table 8 Parameters determined in the fluorescence quenching studies. 
 L1 C1 L2 C2 
KSV / M-1 6.10 × 104 1.20 × 105 4.51× 105 5.15 × 105 
Kq / M-1s-1 6.10 × 1012 1.20 × 1013 4.51× 1013 5.15 × 1013 
Ka / M
-1 1.97 × 105 2.36 × 103 9.81 × 105 2.38 × 106 
N 1.1 0.70 0.99 1.2 
 
3.3.3.1 Determination of binding constant and the number of binding sites 
The following equation (Eqn. 2) can be used to calculate the binding constant (Ka) and the 
number of binding sites (n) for the static quenching interaction, assuming similar and 
independent binding sites in the biomolecule: 
log(F0-F)/F= logKa + nlog[Q]     (2) 
where n is the average number of binding sites per albumin molecule and Ka is the binding 
constant in the protein complex interaction. The double logarithmic plot of log [(F0 – F)/F] 
versus log[Q] is shown in Fig. 15. The Ka and n values, calculated at 298 K, are included in 
Table 8. Values between 103 and 106 M−1 were obtained for Ka indicating weak to strong 
binding to BSA where n values of ca. 1 imply only a binding site in each albumin. C2 shows 
a much higher binding constant than C1, and the complex C2 show higher binding ability than 
its ligand, L2. 
  44 
 
Figure 15 Scatchard plots of log [(F0 − F)/F] vs. log [Q] for determination of the complex- 
BSA binding constant and the number of binding sites on BSA for C1 (A) and C2 (B). 
3.4 DNA binding affinity  
3.4.1 Absorption spectroscopic measurements 
The interaction between metal complexes and DNA is commonly studied by 
electronic absorption spectroscopy since binding to the macromolecule leads to changes in the 
electronic spectrum [68]. Hypochromism and bathochromism generally occur by the 
intercalation of metal complexes to DNA due to strong π–π∗ stacking interactions between the 
aromatic chromophore of the complex and the DNA base pairs [69, 70]. Hyperchromism in 
absorption intensity is usually caused by minor groove binding of complexes to DNA, which 
indicates the unwinding of the DNA double helix and its unstacking and the concomitant 
exposure of the bases [71, 72]. Fig. 16 shows the electronic absorption spectra of the 
complexes in the absence and presence of ctDNA. The spectra mainly consist of intraligand 
and ligand-to-metal charge transfer (LMCT) π → π∗ and n → π∗ transition bands centred at 
296, 350 and 422 nm for complex C1 and 390 and 465 nm for C2. The addition of increasing 
amounts of DNA (up to [DNA]/[complex] = 4.0) significantly changes the UV–vis absorption 
spectra. Decreased absorption intensity (hypochromism) and slight increase in absorption 
wavelength (bathochromism) for both complexes confirms the binding of complexes to DNA 
by intercalation and formation of new complex adducts with double helical ctDNA.  
To elucidate and compare the binding strength of the four compounds with ctDNA 
quantitatively, the results were fitted assuming the formation of a 1:1 association complex 
between DNA and the compounds, 
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Cpx + DNA    Cpx:DNA 𝐾𝑎 =
[Cpx:DNA]
[Cpx][DNA]
 
The total concentration of DNA and compounds are the sum of the concentrations of free and 
associated forms, respectively, 
𝐶DNA = [DNA] + [Cpx:DNA]        (3) 
𝐶Cpx = [Cpx] + [Cpx:DNA]        (4) 
and these can be used to rewrite the concentration of associated form as a function of the total 
concentrations, 𝐶DNA and 𝐶Cpx, and of the binding constant, 𝐾𝑎, 
[Cpx:DNA] =
1
2
(𝐶DNA + 𝐶Cpx +
1
𝐾𝑎
) −
1
2
√(𝐶DNA + 𝐶Cpx +
1
𝐾𝑎
)
2
− 4 ∙ 𝐶DNA ∙ 𝐶Cpx  (5) 
The apparent molar absorptivity of a given solution of a compound and DNA is obtained from 
the molar fraction average of the molar absorptivity of the individual species, 
                     𝜀̅𝜆 =
[𝐶𝑝𝑥]
𝐶Cpx
𝜀Cpx
𝜆 +
[𝐶𝑝𝑥:𝐷𝑁𝐴]
𝐶Cpx
𝜀Cpx:DNA
𝜆          (6) 
The experimental results were fitted using equations 4, 5 and 6 by adjusting the values of molar 
absorptivity of the individual species 𝜀Cpx
𝜆 and 𝜀Cpx:DNA
𝜆  at each wavelength selected and the 
value of the binding constant, 𝐾𝑎, for each compound studied. Upon fitting the data, the 
intrinsic binding constants (Ka) were found to be 4.77 × 10
3, 2.94 × 104, 7.74 × 105 and 
2.73 × 103 for L1, L2, C1 and C2, respectively. C1 has higher binding constant than its Schiff 
base ligand, L1, where coordination with zinc improved the binding of the compound with 
DNA, whereas, C2 has lower binding constant than L1. Moreover, it is apparent that C1 has 
much higher affinity than C2 due to presence of two aromatic pyridines, which are hydrophobic 
and easily insert itself between DNA base-pairs through a combination of π–π stacking and 
hydrophobic interactions [73].   
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Figure 16 Electronic spectra of complexes in buffer solution (PBS, 10 mM, pH 7.4) upon increasing 
of DNA concentration, ranging from 0 to 8.2 × 10−5 M and 0 to  5.6 × 10−5 M for C1 and 
C2 respectively. [Complex] = 2.6 × 10−5 and 2.5 × 10−5 M for C1 and C2 respectively. 
Inset: Variation of the molar absorptivity at wavelengths at 296, 350 and 422 nm for C1 
and 390 and 465 nm for C2 with [DNA]/[Complex] ratio where the lines show the fitted 
model to determine the binding constant of the complex with DNA. 
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 3.4.2 Circular dichroism experiments  
 Circular Dichroism (CD) is one of the best techniques to investigate the conformational 
changes and morphology of DNA [74]. CD spectroscopy is based on the differences between 
the levorotatory and dextrorotatory polarized light absorptions [75]. There are two 
characteristic bands of B type DNA in CD spectra (Fig. 17). The positive band, at 275 nm, 
corresponds to π–π* interaction of bases and the negative one, at 245 nm, is associated with 
the dextrorotatory helix structure [76]. These bands are very sensitive to the DNA interactions 
with other molecules and depend on the interaction type. Covalent and intercalative binding 
are generally well known for affecting the DNA tertiary structure and lead to changes in the 
CD spectra of DNA, whereas less or no perturbation is shown by external binding modes 
(electrostatic interaction or groove binding) on the base stacking and helicity bands [77]. 
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Figure 17  CD spectra of ct-DNA (6 × 10−5 M) in the absence and presence of increasing molar ratio      
of  [complex]/[ct-DNA] ranges from 0:1 to 1:3.01 and 0:1 to 1:2.35 for C1 (A) and C2 (B), 
respectively, in buffered solution (PBS, 10 mM pH = 7.4). 
In this experiment, successive addition of complexes from 0 to 8.2 × 10−5 M and 0 to 5.6 × 10−5 M 
for C1 and C2, respectively, increases the ellipticity of the positive band at 275 nm where 
maximum molar ratio = 4.0 has been reached. For C2 induced circular dichroism bands 
develop above 290 nm, being a clear indication of the interaction of C2 with DNA. The two 
complexes can intercalate into DNA base stacking while the characteristics of the B form CD 
spectrum is still conserved, according to the results. In addition, the arrangement of the DNA 
bases is somewhat altered. Binding of the complexes does not cause significant changes in 
the helix conformation of ct-DNA since no clear variations are observed in the negative 
band [78]. The mode of interaction between the complex and DNA must be intercalative, 
according to the results [79, 80]. 
3.5 In vitro biological activity studies 
3.5.1 Cytotoxic activity 
The in vitro cytotoxicity of L1 and L2 were evaluated on three cell lines (Caco-2, MCF-7 and 
PC-3) and one normal cell, NHDF. Under the same experimental conditions, fluorouracil (5FU) 
was used as a positive control. The activity was measured after 48 h incubation and IC50 values 
for tested compounds and the positive control against the cell lines are listed in Table 9. It is 
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worthwhile to mention that L1 shows higher cytotoxicity towards most cells than 5FU. When 
we compare the IC50 values, it can be found that the IC50 values of L1 are higher than that 
of L2 for all the cancer cell lines, indicating that L1 possessed better activities than L2 under 
identical experimental conditions, however, both of tested compounds show no selectivity 
towards cancer cells. 
Table 9 Cytotoxicity of the ligands (IC50 values in M at 48h incubation) as well as the 
positive control, 5-FU, in Caco-2, MCF-7, PC-3 and NHDF cells. 
 Caco-2 MCF-7 PC-3 NHDF 
L1 3.98 1.36 2.92 1.41 
L2 12.58 14.94 9.73 4.58 
5-FU 0.82 4.93 3.30 17.00 
 
3.5.2 Antimicrobial activity 
The antibacterial and antifungal efficacy of the ligands and one Zn complex, C1, were tested 
against several strains of bacteria and two candida fungi and the results are presented in Table 
10. The results obtained for antimicrobial activity of the compounds showed that L1 is active 
against L. monocytogenes; L2 is active against K. pneumoniae, A. baumannii and S. aureus and 
C1 against L. monocytogenes and S. aureus. The ligand L2 showed better activity against tested 
microbials compared to the other ligand and its metal complex. This higher activity is possibly 
due to interference in the normal cell process of the organism caused by the formation of 
hydrogen bonds through the azomethine group with the active centre of cell constituents [81]. 
Precise observation reveals that the compounds are less active against P. aeruginosa and C. 
tropicalis while more active against L. monocytogenes and S. aureus. C1 showed improved 
activity against S. aureus compared to its free ligand and this enhanced activity of the complex 
may be attributed to chelation of Schiff base with metal ions that provide stability and more 
susceptibility against the bacterial pathogen [82, 83]. It has been suggested that the structural 
components possessing additional (C=N) bond with nitrogen and oxygen donor systems inhibit 
enzyme activity due to their deactivation by metal coordination. This permits their efficient 
permeation through the lipid layer of organisms and destroys their activity [84]. The lower 
antibacterial activity of metal complexes may be due to strong interaction between the imine 
moieties and the metal ions. This type of interaction reduces the activity of imine moieties 
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toward inhibition of bacterial activities whereas the ligand has higher antibacterial activity than 
its metal complexes [85, 86]. 
Table 10 Inhibition halo (mm) and minimum inhibitory concentration MIC (µg/mL) for 
different strains of bacteria and fungi. 
Inhibition halo (mm) 
Compou
nds 
Klebsiella 
pneumoni
ae ATCC 
13883 
Acinetobac
ter 
baumannii 
LMG 1025 
Listeria 
monocytoge
nes LMG 
16779 
Pseudom
onas 
aeruginos
a ATCC 
27853 
Staphyloc
occus 
aureus 
ATCC25
923 
Candida 
albicans 
ATCC 
90028 
Candida 
tropicalis 
ATCC 
750 
L2 6.0±0.0 6.0±0.0 6.0±0.0 6.0±0.0 11.6±0.2 6.0±0.0 6.0±0.0 
L1 6.0±0.0 6.0±0.0 6.0±0.0 6.0±0.0 6.0±0.0 6.0±0.0 6.0±0.0 
C1 6.0±0.0 6.0±0.0 6.7±0.6 6.0±0.0 7.2±0.1 6.0±0.0 6.0±0.0 
MIC (µg/mL) 
L2 16 16 >64 >64 8 64 >64 
L1 >64 >64 8 >64 64 >64 >64 
C1 >128 >128 16 >128 16 >128 >128 
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4. Conclusions 
In the current work Schiff base ligands derived from pyridin-2-yl-hydrazonomethyl phenol and 
methyl-phenol-di-S-methyl dithiocarbazate were synthesized from the condensation of 2, 6-
diformyl-4-methylphenol with 2-hydrazino pyridine and S-methyl carbazate. Both ligands 
were obtained in good yields and fully characterized by a set of analytical techniques, verifying 
the proposed structures.  
The Zn(II) complexes (C1, C2) were synthetized by stirring ethanolic solutions of ligands and 
Zn(CH3COO)2.2H2O. 
1H and 13C NMR experiments were done for all ligands and zinc 
complexes in addition to elemental analysis and other spectroscopic techniques. The 
characterization suggests that the Schiff base L2 coordinates the two metal ions through the 
phenolate-O, the imine-N and sulphur atom in the thiol form, while in C1 the S atom is replaced 
by the pyridinic nitrogen. Acetate ions complete the coordination sphere in both complexes, 
yielding neutral Zn-complexes. 
The stability of the compounds in buffered aqueous media (5 % DMSO and 95 % PBS) was 
evaluated and all are stable at least for three hours. The two Zn(II) complexes were tested for 
their biomolecule binding abilities such as serum albumin and nucleic acid. Various 
spectroscopic techniques were employed to investigate possible interactions of the compounds 
with these biomolecules. The results indicated that there is medium to moderate interaction 
between the complexes and biomolecules.  
Results of biological studies against bacteria and fungi revealed moderate activity of the 
synthesized compounds, however, the results of cytotoxicity study showed that the tested 
compounds are cytotoxic both on cancer and normal cell lines.  
In general, both families of compounds show potential to proceed further for biological studies 
to allow their development as metallodrugs, particularly the Methyl-phenol-di-S-methyl 
dithiocarbazate Zn(II) compound. 
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Appendices 
 
A. NMR spectra 
 
Figure A1 Aromatic region of the 1H NMR spectrum of L1 in DMSO-d6 at room 
temperature. 
 
Figure A2 Aromatic region of the 1H NMR spectrum of C1 in DMSO-d6 at room 
temperature. 
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Figure A3 13C APT NMR spectrum of C1in DMSO-d6 at room temperature. 
 
Figure A4 1H NMR spectrum of L2 in DMSO-d6 at room temperature. 
  63 
 
Figure A5 13C APT NMR spectrum of L2 in DMSO-d6 at room temperature. 
 
Figure A6 1H NMR spectrum of C2 in DMSO-d6 at room temperature 
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Figure A7 13C APT NMR spectrum of C2 in DMSO-d6 at room temperature. 
B. FTIR Spectra 
 
 
Figure C1 FTIR spectra for Schiff base ligand, L1 and zinc complex, C1 in KBR.  
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Figure C2 FTIR spectra for Schiff base ligand, L2 and Zinc complex, C2 in KBR.  
D. ESI-MS spectra  
 
Figure D1 ESI(-) - MS spectra for L1. 
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Figure D2 ESI(+) - MS spectra for L1. 
 
 
Figure D3 ESI(-) - MS spectra for L2. 
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Figure D4 ESI(+) - MS spectra for L2. 
 
Figure D5 ESI(+) - MS spectra for C1. 
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Figure D6 ESI(+) - MS spectra for C1.  
 
Figure D7 ESI(-) - MS spectra for C2. 
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Figure D8 ESI(+) - MS spectra for C2. 
E. Circular Dichroism spectroscopy 
 
Figure E1 CD spectra for interaction of L2 with ctDNA 
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Figure E2 CD spectra for interaction of L1 with ctDNA 
F. UV-vis spectroscopy 
 
 
 
 
 
 
 
 
 
 
Figure F1 UV-vis spectra for interaction of L1 with ctDNA 
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Figure F2 UV-vis spectra for interaction of L2 with ctDNA 
H. UV-vis spectra of stability studies 
 
Figure H1 UV-Vis spectra for stability study of L2 in PBS(pH 7.4, 10 mM, 250C) 
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Figure H1 UV-Vis spectra for stability study of L1 in PBS(pH 7.4, 10 mM, 250C) 
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